Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia
…, B Yu, R Santhanam, H Wang, P Hoellerbauer… - Clinical Cancer …, 2013 - AACR
Purpose: miR-29b directly or indirectly targets genes involved in acute myeloid leukemia (AML),
namely, DNMTs, CDK6, SP1, KIT, and FLT3. Higher miR-29b pretreatment expression is …
namely, DNMTs, CDK6, SP1, KIT, and FLT3. Higher miR-29b pretreatment expression is …
[PDF][PDF] Genome-wide CRISPR-Cas9 screens reveal loss of redundancy between PKMYT1 and WEE1 in glioblastoma stem-like cells
CM Toledo, Y Ding, P Hoellerbauer, RJ Davis… - Cell reports, 2015 - cell.com
To identify therapeutic targets for glioblastoma (GBM), we performed genome-wide CRISPR-Cas9
knockout (KO) screens in patient-derived GBM stem-like cells (GSCs) and human …
knockout (KO) screens in patient-derived GBM stem-like cells (GSCs) and human …
Mitochondrial redox adaptations enable alternative aspartate synthesis in SDH-deficient cells
…, OJ Newsom, K Davidsen, P Hoellerbauer… - Elife, 2023 - elifesciences.org
The oxidative tricarboxylic acid (TCA) cycle is a central mitochondrial pathway integrating
catabolic conversions of NAD+ to NADH and anabolic production of aspartate, a key amino …
catabolic conversions of NAD+ to NADH and anabolic production of aspartate, a key amino …
Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis
F Szulzewsky, S Arora, P Hoellerbauer… - Genes & …, 2020 - genesdev.cshlp.org
YAP1 is a transcriptional coactivator and the principal effector of the Hippo signaling pathway,
which is causally implicated in human cancer. Several YAP1 gene fusions have been …
which is causally implicated in human cancer. Several YAP1 gene fusions have been …
Hyper-active RAS/MAPK introduces cancer-specific mitotic vulnerabilities
…, RR Romain, P Hoellerbauer… - Proceedings of the …, 2022 - National Acad Sciences
Aneuploidy, the incorrect number of whole chromosomes, is a common feature of tumors
that contributes to their initiation and evolution. Preventing aneuploidy requires properly …
that contributes to their initiation and evolution. Preventing aneuploidy requires properly …
[HTML][HTML] SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome
…, P Paschka, P Hoellerbauer… - The Journal of …, 2014 - Am Soc Clin Investig
Aberrant expression of the secreted protein, acidic, cysteine-rich (osteonectin) (SPARC)
gene, which encodes a matricellular protein that participates in normal tissue remodeling, is …
gene, which encodes a matricellular protein that participates in normal tissue remodeling, is …
[HTML][HTML] Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia
Deregulation of microRNAs' expression frequently occurs in acute myeloid leukemia (AML).
Lower miR-181a expression is associated with worse outcomes, but the exact mechanisms …
Lower miR-181a expression is associated with worse outcomes, but the exact mechanisms …
[HTML][HTML] A kinase-deficient NTRK2 splice variant predominates in glioma and amplifies several oncogenic signaling pathways
…, T Ozawa, F Szulzewsky, P Hoellerbauer… - Nature …, 2020 - nature.com
Independent scientific achievements have led to the discovery of aberrant splicing patterns
in oncogenesis, while more recent advances have uncovered novel gene fusions involving …
in oncogenesis, while more recent advances have uncovered novel gene fusions involving …
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia
…, AM Dorrance, C Walker, P Hoellerbauer… - Leukemia, 2013 - nature.com
Histone deacetylase (HDAC) inhibitors either alone or in combination with hypomethylating
agents have limited clinical effect in acute myeloid leukemia (AML). Previously, we …
agents have limited clinical effect in acute myeloid leukemia (AML). Previously, we …
inv(16)/t(16;16) acute myeloid leukemia with non–type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations
…, P Paschka, AK Eisfeld, P Hoellerbauer… - Blood, The Journal …, 2013 - ashpublications.org
The inv(16)(p13q22)/t(16;16)(p13;q22) in acute myeloid leukemia results in multiple CBFB-MYH11
fusion transcripts, with type A being most frequent. The biologic and prognostic …
fusion transcripts, with type A being most frequent. The biologic and prognostic …